Cristofanilli, Massimo

Publications

Sort by

Co-Author Network

selected publications

Dynamic glycoprotein hyposialylation promotes chemotherapy evasion and metastatic seeding of quiescent circulating tumor cell clusters in breast cancer. Cancer discovery. 2023 Academic Article GET IT
Genetic alterations detected by circulating tumor DNA in HER2-low metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023 Academic Article GET IT
ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer. Cancers. 2023 Academic Article GET IT
Times cited: 5
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO precision oncology. 2023 Academic Article GET IT
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future oncology (London, England). 2023 Academic Article GET IT
Computational ranking-assisted identification of Plexin-B2 in homotypic and heterotypic clustering of circulating tumor cells in breast cancer metastasis. bioRxiv : the preprint server for biology. 2023 Article GET IT
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Article GET IT
Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date. OncoTargets and therapy. 2023 Review GET IT
Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary. Future oncology (London, England). 2023 Review GET IT
Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity. Science advances. 2023 Academic Article GET IT
Times cited: 1
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. Cancers. 2023 Academic Article GET IT
Times cited: 9152
A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases. Clinical breast cancer. 2022 Academic Article GET IT
Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer. EBioMedicine. 2022 Academic Article GET IT
Times cited: 2
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix^® PC1 System. Cancers. 2022 Academic Article GET IT
Times cited: 72
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. NPJ breast cancer. 2022 Academic Article GET IT
Times cited: 2099
Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity. eLife. 2022 Academic Article GET IT
Times cited: 3
MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer. Cells. 2022 Academic Article GET IT
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. NPJ precision oncology. 2022 Academic Article GET IT
Times cited: 11492
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Academic Article GET IT
Times cited: 23
CDC20-Mediated hnRNPU Ubiquitination Regulates Chromatin Condensation and Anti-Cancer Drug Response. Cancers. 2022 Academic Article GET IT
Times cited: 30
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. The oncologist. 2022 Academic Article GET IT
Times cited: 4
Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer. International journal of molecular sciences. 2022 Academic Article GET IT
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism. Cancers. 2022 Academic Article GET IT
Times cited: 90
Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. JCO precision oncology. 2022 Academic Article GET IT
CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome. Breast cancer research : BCR. 2022 Academic Article GET IT
Times cited: 4
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer treatment reviews. 2022 Review GET IT
Times cited: 22
Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer research. 2022 Academic Article GET IT
Times cited: 10
Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?. British journal of cancer. 2022 Review GET IT
Times cited: 12
Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. Theranostics. 2022 Academic Article GET IT
Times cited: 13
Positive predictive value of ERBB2 copy number gain by tissue or circulating tumor DNA next-generation sequencing across advanced cancers. Oncotarget. 2022 Academic Article GET IT
Times cited: 2
Leptomeningeal metastases: the future is now. Journal of neuro-oncology. 2022 Review GET IT
Times cited: 3
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. NPJ breast cancer. 2022 Academic Article GET IT
Times cited: 2
Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. Cancers. 2021 Academic Article GET IT
Times cited: 2
Standard of Care in Hormone Receptor-Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?. JCO oncology practice. 2021 Comment GET IT
Times cited: 1
Liquid biopsy from research to clinical practice: focus on non-small cell lung cancer. Expert review of molecular diagnostics. 2021 Review GET IT
Times cited: 9
Understanding metastasis in breast cancer to improve detection, monitoring and treatment. Critical reviews in oncology/hematology. 2021 Letter GET IT
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer. Cell chemical biology. 2021 Academic Article GET IT
Times cited: 3
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. Breast cancer research and treatment. 2021 Academic Article GET IT
Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC). International journal of molecular sciences. 2021 Academic Article GET IT
ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nature communications. 2021 Academic Article GET IT
Times cited: 55
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. The oncologist. 2021 Academic Article GET IT
Times cited: 11
Longitudinal Dynamics of Circulating Tumor Cells and Circulating Tumor DNA for Treatment Monitoring in Metastatic Breast Cancer. JCO precision oncology. 2021 Academic Article GET IT
Times cited: 2
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3. The oncologist. 2021 Academic Article GET IT
Times cited: 14
Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer. Breast cancer research and treatment. 2021 Academic Article GET IT
Times cited: 5
Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. eLife. 2021 Academic Article GET IT
Times cited: 9
Whole-exome sequencing identifies somatic mutations and intratumor heterogeneity in inflammatory breast cancer. NPJ breast cancer. 2021 Academic Article GET IT
Times cited: 604
Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. Cancers. 2021 Academic Article GET IT
Times cited: 9
EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer. Theranostics. 2021 Academic Article GET IT
Times cited: 15
New Treatment Strategies for the Inflammatory Breast Cancer. Current treatment options in oncology. 2021 Review GET IT
Times cited: 4
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. Breast cancer research : BCR. 2021 Academic Article GET IT
Times cited: 46
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up. The oncologist. 2021 Academic Article GET IT
Times cited: 18
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. Journal of the National Cancer Institute. 2021 Academic Article GET IT
Times cited: 38
Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics. Communications biology. 2021 Academic Article GET IT
Times cited: 21
Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. JCO global oncology. 2021 Academic Article GET IT
Times cited: 30
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 15
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools. European journal of cancer (Oxford, England : 1990). 2020 Academic Article GET IT
Times cited: 22
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer. Breast cancer research : BCR. 2020 Academic Article GET IT
Times cited: 9
New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy. EMBO molecular medicine. 2020 Academic Article GET IT
Times cited: 8
IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?. Annals of translational medicine. 2020 Editorial Article GET IT
Times cited: 258
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute. 2020 Review GET IT
Times cited: 41
Precision Prevention and Cancer Interception: The New Challenges of Liquid Biopsy. Cancer discovery. 2020 Review GET IT
Times cited: 35
International liquid biopsy standardization alliance white paper. Critical reviews in oncology/hematology. 2020 Review GET IT
Times cited: 46
Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer: Positive, Negative, or a More Complex Issue?. JAMA oncology. 2020 Editorial Article GET IT
Times cited: 1
Corrigendum to "Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)" [Crit. Rev. Oncol. Hematol. 151 (July) (2020) 102978]. Critical reviews in oncology/hematology. 2020 Article GET IT
Times cited: 3
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast cancer research and treatment. 2020 Academic Article GET IT
Times cited: 12
Oncological care organisation during COVID-19 outbreak. ESMO open. 2020 Academic Article GET IT
Times cited: 27
Landscape of circulating tumour DNA in metastatic breast cancer. EBioMedicine. 2020 Academic Article GET IT
Times cited: 29
Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical reviews in oncology/hematology. 2020 Review GET IT
Times cited: 60
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast cancer research and treatment. 2020 Academic Article GET IT
Times cited: 19
The Landscape of Targeted Therapies in TNBC. Cancers. 2020 Review GET IT
Times cited: 119
Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents. The oncologist. 2020 Review GET IT
Times cited: 10
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies. Breast cancer research : BCR. 2020 Academic Article GET IT
Times cited: 23
Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance. Cellular signalling. 2020 Academic Article GET IT
Times cited: 6
Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer. International journal of molecular sciences. 2020 Academic Article GET IT
Times cited: 8
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 26
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Molecular oncology. 2020 Academic Article GET IT
Times cited: 15
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer. Journal for immunotherapy of cancer. 2020 Academic Article GET IT
Times cited: 45
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC). Critical reviews in oncology/hematology. 2019 Review GET IT
Times cited: 14
Time for a shift in molecular down staging in luminal breast cancer. The Lancet. Oncology. 2019 Comment GET IT
Times cited: 3
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer. Breast cancer research : BCR. 2019 Academic Article GET IT
Times cited: 35
A novel strategy to block mitotic progression for targeted therapy. EBioMedicine. 2019 Academic Article GET IT
Times cited: 28
The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells. Seminars in cancer biology. 2019 Review GET IT
Times cited: 21
Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clinical chemistry. 2019 Academic Article GET IT
Times cited: 44
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. The Lancet. Oncology. 2019 Review GET IT
Times cited: 96
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. The breast journal. 2019 Academic Article GET IT
Times cited: 6
Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. Therapeutic advances in medical oncology. 2019 Academic Article GET IT
Times cited: 31
Emerging Role of Genomics and Cell-Free DNA in Breast Cancer. Current treatment options in oncology. 2019 Review GET IT
Times cited: 9
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology. Expert review of anticancer therapy. 2019 Review GET IT
Times cited: 12
Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer. BMC cancer. 2019 Academic Article GET IT
Times cited: 27
Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer. 2019 Review GET IT
Times cited: 10
A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy. EBioMedicine. 2019 Academic Article GET IT
Times cited: 19
Elevated serum levels of sialyl Lewis X (sLe^X) and inflammatory mediators in patients with breast cancer. Breast cancer research and treatment. 2019 Academic Article GET IT
Times cited: 14
Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms. Cancer. 2019 Academic Article GET IT
Times cited: 5
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. 2019 Academic Article GET IT
Times cited: 124
Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer. Anticancer research. 2019 Academic Article GET IT
Times cited: 44
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 43
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nature communications. 2019 Academic Article GET IT
Times cited: 185
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 189
Palbociclib and Fulvestrant in Breast Cancer. Reply. The New England journal of medicine. 2019 Letter GET IT
Times cited: 2
Current state of clinical trials in breast cancer brain metastases. Neuro-oncology practice. 2019 Academic Article GET IT
Times cited: 16
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer treatment reviews. 2019 Review GET IT
Times cited: 76
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical reviews in oncology/hematology. 2018 Review GET IT
Times cited: 156
Antineoplastic effects of selective CDK9 inhibition with atuveciclib on cancer stem-like cells in triple-negative breast cancer. Oncotarget. 2018 Academic Article GET IT
Times cited: 16
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA. European journal of cancer (Oxford, England : 1990). 2018 Academic Article GET IT
Times cited: 25
Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models. Cancer discovery. 2018 Academic Article GET IT
Times cited: 192
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England journal of medicine. 2018 Academic Article GET IT
Times cited: 655
Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 40
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 53
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3. European journal of cancer (Oxford, England : 1990). 2018 Academic Article GET IT
Times cited: 45
Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. JAMA oncology. 2018 Letter GET IT
Times cited: 2
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial. Cancer discovery. 2018 Academic Article GET IT
Times cited: 293
Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy. Molecular cancer research : MCR. 2018 Academic Article GET IT
Times cited: 6
NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity. Free radical biology & medicine. 2018 Academic Article GET IT
Times cited: 9
Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. JAMA oncology. 2018 Academic Article GET IT
Times cited: 99
Caloric restriction counteracts chemotherapy-induced inflammation and increases response to therapy in a triple negative breast cancer model. Cell cycle (Georgetown, Tex.). 2018 Academic Article GET IT
Times cited: 32
From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Academic Article GET IT
Times cited: 13
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. Oncotarget. 2018 Academic Article GET IT
Times cited: 9
Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy. Breast cancer research and treatment. 2018 Academic Article GET IT
Times cited: 81
Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Human pathology. 2018 Academic Article GET IT
Times cited: 21
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget. 2018 Academic Article GET IT
Times cited: 72
International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. Journal of Cancer. 2018 Academic Article GET IT
Times cited: 72
Comparing the Performances of Magnetic Resonance Imaging Size vs Pharmacokinetic Parameters to Predict Response to Neoadjuvant Chemotherapy and Survival in Patients With Breast Cancer. Current problems in diagnostic radiology. 2018 Academic Article GET IT
Times cited: 12
Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 25
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 59
Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nature communications. 2018 Academic Article GET IT
Times cited: 252
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. JCO precision oncology. 2018 Academic Article GET IT
Times cited: 38
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer research. 2018 Academic Article GET IT
Times cited: 139
Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer. Clinical pharmacology and therapeutics. 2018 Review GET IT
Times cited: 6
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. Cancer research. 2018 Academic Article GET IT
Times cited: 80
Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8⁺ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. European urology. 2017 Review GET IT
Times cited: 34
Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 99
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. European journal of cancer (Oxford, England : 1990). 2017 Review GET IT
Times cited: 26
Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10^th Anniversary Conference. Journal of Cancer. 2017 Academic Article GET IT
Times cited: 10
Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?. Oncotarget. 2017 Review GET IT
Times cited: 10
Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Breast cancer research and treatment. 2017 Academic Article GET IT
Times cited: 24
Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 59
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. The oncologist. 2017 Academic Article GET IT
Times cited: 95
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017 Academic Article GET IT
Times cited: 39
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 127
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. Molecular cancer therapeutics. 2017 Academic Article GET IT
Times cited: 86
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 58
Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients. Breast cancer research and treatment. 2017 Academic Article GET IT
Times cited: 34
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Review GET IT
Times cited: 224
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget. 2017 Review GET IT
Times cited: 16
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget. 2017 Review GET IT
Times cited: 91
Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development. Cancer treatment reviews. 2017 Review GET IT
Times cited: 106
Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Review GET IT
Times cited: 26
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Current treatment options in oncology. 2017 Review GET IT
Times cited: 38
Metastatic breast cancer: focus on endocrine sensitivity. Lancet (London, England). 2016 Comment GET IT
Times cited: 1
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. The oncologist. 2016 Academic Article GET IT
Times cited: 19
Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 26
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 128
Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016 Academic Article GET IT
Times cited: 79
Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer. International journal of molecular sciences. 2016 Academic Article GET IT
Times cited: 57
Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 22
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less. Breast (Edinburgh, Scotland). 2016 Academic Article GET IT
Times cited: 12
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC cancer. 2016 Academic Article GET IT
Times cited: 27
GSK-3 inhibition overcomes chemoresistance in human breast cancer. Cancer letters. 2016 Academic Article GET IT
Times cited: 49
Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). The oncologist. 2016 Academic Article GET IT
Times cited: 158
Prospective changes in global DNA methylation and cancer incidence and mortality. British journal of cancer. 2016 Academic Article GET IT
Times cited: 30
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 478
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. Journal of Cancer. 2016 Academic Article GET IT
Times cited: 62
Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2016 Academic Article GET IT
Times cited: 47
Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. Breast cancer research : BCR. 2016 Academic Article GET IT
Times cited: 33
Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers. Oncotarget. 2016 Academic Article GET IT
Times cited: 11
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Molecular cancer therapeutics. 2016 Academic Article GET IT
Times cited: 38
Is Personalized Medicine Here?. Oncology (Williston Park, N.Y.). 2016 Review GET IT
Times cited: 13
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 117
Inflammatory breast cancer: a new approach. The Lancet. Oncology. 2016 Comment GET IT
Times cited: 3
The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells. Breast cancer research : BCR. 2016 Academic Article GET IT
Times cited: 19
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 1146
MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2016 Academic Article GET IT
Times cited: 31
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. Breast cancer research : BCR. 2016 Academic Article GET IT
Times cited: 60
CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC cancer. 2016 Academic Article GET IT
Times cited: 49
Development of an Automated and Sensitive Microfluidic Device for Capturing and Characterizing Circulating Tumor Cells (CTCs) from Clinical Blood Samples. PloS one. 2016 Academic Article GET IT
Times cited: 66
Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. RSC advances. 2016 Academic Article GET IT
Times cited: 26
Breast Cancer Stem Cell Isolation. Methods in molecular biology (Clifton, N.J.). 2016 Academic Article GET IT
Times cited: 22
Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Breast cancer research and treatment. 2015 Academic Article GET IT
Times cited: 95
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. The New England journal of medicine. 2015 Letter GET IT
Times cited: 4
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast cancer research and treatment. 2015 Academic Article GET IT
Times cited: 55
A Preclinical Model of Inflammatory Breast Cancer to Study the Involvement of CXCR4 and ACKR3 in the Metastatic Process. Translational oncology. 2015 Academic Article GET IT
Times cited: 13
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast cancer research and treatment. 2015 Academic Article GET IT
Times cited: 16
Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells. EBioMedicine. 2015 Academic Article GET IT
Times cited: 31
The effects of erythropoiesis-stimulating agents on the short-term and long-term survivals in metastatic breast cancer patients receiving chemotherapy: a SEER population-based study. Breast cancer research and treatment. 2015 Academic Article GET IT
Times cited: 2
Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. PloS one. 2015 Academic Article GET IT
Times cited: 81
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic proceedings. 2015 Academic Article GET IT
Times cited: 122
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 2015 GET IT
Times cited: 249
Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American journal of clinical oncology. 2015 Academic Article GET IT
Times cited: 20
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 1039
Using circulating tumor cells to guide therapy in breast cancer: could this replace biopsies?. Pharmacogenomics. 2015 Editorial Article GET IT
Times cited: 1
IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model. Journal of the National Cancer Institute. Monographs. 2015 Academic Article GET IT
Times cited: 6
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). Journal of the National Cancer Institute. Monographs. 2015 Conference Paper GET IT
Times cited: 29
Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. Journal of the National Cancer Institute. Monographs. 2015 Academic Article GET IT
Molecular characterization and targeted therapeutic approaches in breast cancer. Breast cancer research : BCR. 2015 Review GET IT
Times cited: 118
Blocking the adhesion cascade at the premetastatic niche for prevention of breast cancer metastasis. Molecular therapy : the journal of the American Society of Gene Therapy. 2015 Academic Article GET IT
Times cited: 43
Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients. The breast journal. 2015 Academic Article GET IT
Times cited: 38
Circulating tumor cells in newly diagnosed inflammatory breast cancer. Breast cancer research : BCR. 2015 Academic Article GET IT
Times cited: 36
Cytometric characterization of circulating tumor cells captured by microfiltration and their correlation to the CellSearch(®) CTC test. Cytometry. Part A : the journal of the International Society for Analytical Cytology. 2014 Academic Article GET IT
Times cited: 113
CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer research. 2014 Academic Article GET IT
Times cited: 51
Cancer stem cells: implications for cancer therapy. Oncology (Williston Park, N.Y.). 2014 Review GET IT
Times cited: 269
Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer. Thrombosis and haemostasis. 2014 Academic Article GET IT
Times cited: 28
CTC enumeration and characterization: moving toward personalized medicine. Annals of translational medicine. 2014 Review GET IT
Times cited: 119
PARP inhibitors for chemoprevention--letter. Cancer prevention research (Philadelphia, Pa.). 2014 Letter GET IT
Times cited: 3
Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables. Cancer causes & control : CCC. 2014 Academic Article GET IT
Times cited: 13
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast cancer research : BCR. 2014 Academic Article GET IT
Times cited: 85
Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy. Breast cancer research and treatment. 2014 Academic Article GET IT
Times cited: 1
Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast cancer research : BCR. 2014 Academic Article GET IT
Times cited: 90
Inflammatory breast cancer management in the national comprehensive cancer network: the disease, recurrence pattern, and outcome. Clinical breast cancer. 2014 Academic Article GET IT
Times cited: 58
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. Journal of experimental & clinical cancer research : CR. 2014 Academic Article GET IT
Times cited: 18
Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells. Journal of Cancer. 2014 Academic Article GET IT
Survival of women with inflammatory breast cancer: a large population-based study. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 51
Circulating tumour cells: telling the truth about metastasis. The Lancet. Oncology. 2014 Comment GET IT
Times cited: 19
Circulating giant macrophages as a potential biomarker of solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 173
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy. 2014 GET IT
Times cited: 40
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 441
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 70
The Third International Inflammatory Breast Cancer Conference. Breast cancer research : BCR. 2013 Conference Paper GET IT
Times cited: 9
Presence of anaplastic lymphoma kinase in inflammatory breast cancer. SpringerPlus. 2013 Academic Article GET IT
Times cited: 121
A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 9
Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. 2013 GET IT
Times cited: 20
EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells. Journal of experimental & clinical cancer research : CR. 2013 Academic Article GET IT
Times cited: 33
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 18
Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 54
Circulating tumor DNA to monitor metastatic breast cancer. The New England journal of medicine. 2013 Letter GET IT
Times cited: 17
Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 27
Inflammatory breast cancer (IBC): clues for targeted therapies. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 63
Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?. Journal of cancer research and clinical oncology. 2013 Academic Article GET IT
Times cited: 29
Genome wide proteomics of ERBB2 and EGFR and other oncogenic pathways in inflammatory breast cancer. Journal of proteome research. 2013 Academic Article GET IT
Times cited: 34
Genomic and expression analysis of microdissected inflammatory breast cancer. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 39
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 107
Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 39
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. Journal of experimental therapeutics & oncology. 2013 Academic Article GET IT
Times cited: 41
A chromosome-centric human proteome project (C-HPP) to characterize the sets of proteins encoded in chromosome 17. Journal of proteome research. 2012 Academic Article GET IT
Times cited: 32
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast cancer research and treatment. 2012 Academic Article GET IT
Times cited: 50
Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2012 Academic Article GET IT
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Molecular cancer therapeutics. 2012 Academic Article GET IT
Times cited: 175
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer. 2012 Academic Article GET IT
Times cited: 60
Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. British journal of cancer. 2012 Academic Article GET IT
Times cited: 49
Considerations in the development of circulating tumor cell technology for clinical use. Journal of translational medicine. 2012 Review GET IT
Times cited: 278
Brain metastasis in breast cancer: last barrier to the cure?. Oncology (Williston Park, N.Y.). 2012 Comment GET IT
Times cited: 2
Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clinical breast cancer. 2012 Academic Article GET IT
Times cited: 80
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone. Journal of oncology. 2012 Academic Article GET IT
Times cited: 10
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast cancer research and treatment. 2012 Academic Article GET IT
Times cited: 51
CTCs in metastatic breast cancer. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 2012 Review GET IT
Times cited: 28
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Annals of surgical oncology. 2011 Conference Paper GET IT
Times cited: 377
Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. The oncologist. 2011 Academic Article GET IT
Times cited: 76
Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system. International journal of cancer. 2011 Academic Article GET IT
Times cited: 184
A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer. Cancer. 2011 Academic Article GET IT
Times cited: 20
The use of bevacizumab among women with metastatic breast cancer: a survey on clinical practice and the ongoing controversy. Cancer. 2011 Academic Article GET IT
Times cited: 24
MRI features of inflammatory breast cancer. AJR. American journal of roentgenology. 2011 Academic Article GET IT
Times cited: 56
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 99
Circulating tumor cells and PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011 Review GET IT
Times cited: 12
Identifying factors that impact survival among women with inflammatory breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Academic Article GET IT
Times cited: 43
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast cancer research and treatment. 2011 Academic Article GET IT
Times cited: 28
Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 2011 Academic Article GET IT
Times cited: 59
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast cancer research : BCR. 2011 Academic Article GET IT
Times cited: 184
Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. International journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 73
Serum HER2 levels determined by two methods in patients with metastatic breast cancer. International journal of clinical oncology. 2011 Academic Article GET IT
Times cited: 8
Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. Cancer biology & therapy. 2011 Academic Article GET IT
Times cited: 17
Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. International journal of cancer. 2011 Academic Article GET IT
Times cited: 132
Circulating tumor cells in breast cancer: a tool whose time has come of age. BMC medicine. 2011 Review GET IT
Times cited: 53
Inflammatory breast cancer: what progress have we made?. Oncology (Williston Park, N.Y.). 2011 Review GET IT
Times cited: 37
Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype. European journal of cancer (Oxford, England : 1990). 2011 Academic Article GET IT
Times cited: 78
Inflammatory breast cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2011 Review GET IT
Times cited: 17
Recurrent granulomatous mastitis mimicking inflammatory breast cancer. 2011 GET IT
Times cited: 12
Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. 2011 GET IT
Times cited: 7
A global approach to inflammatory breast cancer. Future oncology (London, England). 2011 Conference Paper GET IT
Times cited: 4
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast cancer research and treatment. 2010 Academic Article GET IT
Times cited: 58
Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 59
Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. Cancer. 2010 Academic Article GET IT
Times cited: 114
Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. International journal of cancer. 2010 Academic Article GET IT
Times cited: 90
Inflammatory breast cancer: the disease, the biology, the treatment. CA: a cancer journal for clinicians. 2010 Review GET IT
Times cited: 262
Molecular mechanisms of metastasis in breast cancer--clinical applications. Nature reviews. Clinical oncology. 2010 Review GET IT
Times cited: 191
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 177
Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PloS one. 2010 Academic Article GET IT
Times cited: 139
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Academic Article GET IT
Times cited: 61
Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. Journal of biomolecular screening. 2010 Academic Article GET IT
Times cited: 54
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010 Academic Article GET IT
Times cited: 106
Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Molecular cancer. 2010 Academic Article GET IT
Times cited: 64
Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. The breast journal. 2010 Academic Article GET IT
Times cited: 23
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 110
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Conference Paper GET IT
Times cited: 357
Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Academic Article GET IT
Times cited: 67
Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer. 2010 Academic Article GET IT
Times cited: 45
Novel targeted therapies in inflammatory breast cancer. Cancer. 2010 Academic Article GET IT
Times cited: 11
Proceedings of the First International Inflammatory Breast Cancer Conference. Cancer. 2010 Editorial Article GET IT
Times cited: 5
Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids. Cancer. 2010 Academic Article GET IT
Times cited: 22
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors. International journal of cancer. 2010 Academic Article GET IT
Times cited: 46
Incidence of and survival following brain metastases among women with inflammatory breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2010 Academic Article GET IT
Times cited: 28
Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. The breast journal. 2010 Letter GET IT
Times cited: 28
Circulating tumor cells revisited. JAMA. 2010 Academic Article GET IT
Times cited: 39
Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clinical & experimental metastasis. 2010 Academic Article GET IT
Times cited: 40
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 148
Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. International journal of radiation oncology, biology, physics. 2010 Academic Article GET IT
Times cited: 40
Dyadic coping in metastatic breast cancer. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2010 Academic Article GET IT
Times cited: 240
Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099. Cancer. 2010 Academic Article GET IT
Times cited: 10
Circulating tumor cells as prognostic marker in metastatic breast cancer. Expert review of anticancer therapy. 2010 Review GET IT
Times cited: 28
Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clinical breast cancer. 2010 Academic Article GET IT
Times cited: 12
CXCR4 expression in early breast cancer and risk of distant recurrence. The oncologist. 2009 Academic Article GET IT
Times cited: 56
GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer. Breast cancer research and treatment. 2009 Academic Article GET IT
Times cited: 63
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients. British journal of cancer. 2009 Academic Article GET IT
Times cited: 46
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 Academic Article GET IT
Times cited: 98
Inflammatory breast cancer. Seminars in radiation oncology. 2009 Review GET IT
Times cited: 48
The biological information obtainable from circulating tumor cells. Breast (Edinburgh, Scotland). 2009 Academic Article GET IT
Times cited: 29
Circulating tumor cells and bone metastases as detected by FDG-PET/CT in patients with metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 77
Circulating tumor cells in metastatic inflammatory breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 24
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. International journal of radiation oncology, biology, physics. 2009 Conference Paper GET IT
Times cited: 9
Re: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. Journal of the National Cancer Institute. 2009 Letter GET IT
Times cited: 6
Breast cancer metastasis: challenges and opportunities. Cancer research. 2009 Academic Article GET IT
Times cited: 175
Molecular targets for treatment of inflammatory breast cancer. Nature reviews. Clinical oncology. 2009 Review GET IT
Times cited: 47
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 129
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. Journal of neuro-oncology. 2009 Academic Article GET IT
Times cited: 72
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Academic Article GET IT
Times cited: 68
Nanotechnology for breast cancer therapy. Biomedical microdevices. 2009 Review GET IT
Times cited: 129
Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2009 Academic Article GET IT
Times cited: 85
Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT. European journal of nuclear medicine and molecular imaging. 2009 Academic Article GET IT
Times cited: 11
Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. 2009 GET IT
Times cited: 17
Dielectric cell separation of fine needle aspirates from tumor xenografts. Journal of separation science. 2008 Academic Article GET IT
Times cited: 20
Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 53
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. Cancer. 2008 Academic Article GET IT
Times cited: 140
Risk of ipsilateral lung cancer after postmastectomy radiotherapy and smoking: does the possible triumph over the actual?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Letter GET IT
Times cited: 1
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. The Journal of surgical research. 2008 Academic Article GET IT
Times cited: 146
Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast cancer research and treatment. 2008 Academic Article GET IT
Times cited: 36
Circulating tumor cells in breast cancer: fiction or reality?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Letter GET IT
Times cited: 16
Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer. 2008 Academic Article GET IT
Times cited: 30
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Academic Article GET IT
Times cited: 74
Molecular dissection of cancers - another piece in the puzzle to better assess, and treat, disease using biomarkers that correlate with disease type and stage. Personalized medicine. 2008 Academic Article GET IT
Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer. 2008 Academic Article GET IT
Times cited: 52
Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. International journal of radiation oncology, biology, physics. 2008 Academic Article GET IT
Times cited: 114
Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008 Academic Article GET IT
Times cited: 162
The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response. Expert opinion on medical diagnostics. 2008 Academic Article GET IT
Times cited: 11
Prognostic value of body mass index in locally advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Academic Article GET IT
Times cited: 110
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast cancer research and treatment. 2008 Academic Article GET IT
Times cited: 72
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 2146
Defining the clinical diagnosis of inflammatory breast cancer. Seminars in oncology. 2008 Review GET IT
Times cited: 51
Inflammatory breast cancer: defining a new entity. Seminars in oncology. 2008 Article GET IT
Times cited: 1
The medical treatment of inflammatory breast cancer. Seminars in oncology. 2008 Review GET IT
Times cited: 32
Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. 2008 Academic Article GET IT
Times cited: 47
Breast cancer in the asian Indian population of the United States: a call for screening and education. The breast journal. 2008 Letter GET IT
Times cited: 2
Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. Journal of experimental therapeutics & oncology. 2008 Academic Article GET IT
Times cited: 48
Prognostic value of initial clinical disease stage after achieving pathological complete response. The oncologist. 2008 Academic Article GET IT
Times cited: 22
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer. 2007 Academic Article GET IT
Times cited: 163
Endocrine resistance in breast cancer: what really matters?. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Editorial Article GET IT
Times cited: 9
Trends for inflammatory breast cancer: is survival improving?. The oncologist. 2007 Academic Article GET IT
Times cited: 99
Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast cancer research and treatment. 2007 Review GET IT
Times cited: 152
Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer. 2007 Review GET IT
Times cited: 106
A gene signature in breast cancer. The New England journal of medicine. 2007 Letter GET IT
What progress have we made in managing inflammatory breast cancer?. Oncology (Williston Park, N.Y.). 2007 Review GET IT
Times cited: 25
New generation of molecular prognostic and predictive tests for breast cancer. Seminars in oncology. 2007 Review GET IT
Times cited: 30
Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2007 Academic Article GET IT
Times cited: 133
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clinical breast cancer. 2007 Academic Article GET IT
Times cited: 139
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 1097
Integrating circulating tumor cell assays into the management of breast cancer. Current treatment options in oncology. 2007 Review GET IT
Times cited: 25
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2007 Academic Article GET IT
Times cited: 42
Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clinical breast cancer. 2006 Academic Article GET IT
Times cited: 21
Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?. Proceedings of the National Academy of Sciences of the United States of America. 2006 Comment GET IT
Times cited: 56
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 666
Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer. Clinical breast cancer. 2006 Academic Article GET IT
Times cited: 22
A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach. Cancer. 2006 Academic Article GET IT
Times cited: 45
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 840
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Seminars in oncology. 2006 Review GET IT
Times cited: 157
High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone marrow transplantation. 2006 Academic Article GET IT
Times cited: 4
Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 179
The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. Future oncology (London, England). 2006 Review GET IT
Times cited: 10
Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006 Academic Article GET IT
Times cited: 55
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 482
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Annals of oncology : official journal of the European Society for Medical Oncology. 2006 Academic Article GET IT
Times cited: 116
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 83
Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 87
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer. Cancer chemotherapy and pharmacology. 2005 Academic Article GET IT
Times cited: 4
Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors. Cancer. 2005 Academic Article GET IT
Times cited: 68
Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2005 Academic Article GET IT
Times cited: 58
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 1537
Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005 Academic Article GET IT
Times cited: 48
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 368
Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence. Cancer. 2005 Academic Article GET IT
Times cited: 42
Inflammatory breast cancer and high-dose chemotherapy: back to the past. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Letter GET IT
CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 86
Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 149
Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005 Academic Article GET IT
Times cited: 191
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 936
The "microscopic" revolution in breast carcinoma. Cancer. 2005 Editorial Article GET IT
Times cited: 10
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 1050
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 315
Systemic treatments for inflammatory breast cancer. Breast disease. 2005 Review GET IT
Times cited: 13
Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study. Cancer. 2004 Academic Article GET IT
Times cited: 14
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004 Academic Article GET IT
Times cited: 65
p53 expression as a prognostic marker in inflammatory breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 56
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer. 2004 Academic Article GET IT
Times cited: 19
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England journal of medicine. 2004 Academic Article GET IT
Times cited: 3713
Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Annals of surgical oncology. 2004 Academic Article GET IT
Times cited: 62
Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clinical breast cancer. 2004 Review GET IT
Times cited: 96
Inflammatory breast carcinoma: the sphinx of breast cancer research. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Letter GET IT
Times cited: 13
Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective. The oncologist. 2004 Conference Paper GET IT
Times cited: 5
Expression of c-kit proto-oncogene product in breast tissue. The breast journal. 2004 Academic Article GET IT
Times cited: 27
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 65
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma. Cancer. 2003 Academic Article GET IT
Times cited: 25
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 9
Chest wall recurrence after mastectomy does not always portend a dismal outcome. Annals of surgical oncology. 2003 Academic Article GET IT
Times cited: 65
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 196
Nipple aspirate fluid cytology in breast carcinoma. Cancer. 2003 Academic Article GET IT
Times cited: 44
High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 31
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer journal (Sudbury, Mass.). 2003 Academic Article GET IT
Times cited: 128
Update on the management of inflammatory breast cancer. The oncologist. 2003 Review GET IT
Times cited: 119
Fingerprinting the circulating repertoire of antibodies from cancer patients. Nature biotechnology. 2002 Academic Article GET IT
Times cited: 292
Molecular targets in breast cancer: current status and future directions. Endocrine-related cancer. 2002 Review GET IT
Times cited: 15
Molecular prognostic factors for breast cancer metastasis and survival. Seminars in radiation oncology. 2002 Review GET IT
Times cited: 74
Angiogenesis modulation in cancer research: novel clinical approaches. Nature reviews. Drug discovery. 2002 Review GET IT
Times cited: 184
Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma. Cancer. 2002 Academic Article GET IT
Times cited: 3
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 504
Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 54
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer chemotherapy and pharmacology. 2001 Academic Article GET IT
Times cited: 41
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Academic Article GET IT
Times cited: 68
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 545
Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 95
New horizons in treating metastatic disease. Clinical breast cancer. 2001 Review GET IT
Times cited: 16
Experience with 9-cis retinoic acid in patients with relapsed and refractory non-Hodgkin's lymphoma. Leukemia & lymphoma. 2000 Academic Article GET IT
Times cited: 10
Primary inflammatory carcinoma of the breast: retrospective review of mammographic findings. AJR. American journal of roentgenology. 2000 Academic Article GET IT
Times cited: 52
Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer treatment reviews. 1999 Review GET IT
Times cited: 23
Bisphosphonates in the Management of Breast Cancer. Cancer control : journal of the Moffitt Cancer Center. 1999 Academic Article GET IT
Times cited: 8
Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast cancer research and treatment. 1999 Academic Article GET IT
Times cited: 11
Phase II study of adozelesin in untreated metastatic breast cancer. Anti-cancer drugs. 1998 Academic Article GET IT
Times cited: 33
Current methods to prevent the development of breast cancer. In vivo (Athens, Greece). 1998 Review GET IT
Times cited: 2

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

A Program for Metastatic Breast Cancer Research awarded by METAvivor Research and Support, Inc. Principal Investigator 2023 - 2026
Development of a platform for high throughput drug screening on CTC-derived organoid in breast and colorectal cancer awarded by National Foundation For Cancer Research Principal Investigator 2022 - 2023

more ...

less ...

Background

education and training

M.D., La Sapienza University (Italy) 1986

Contact

full name

Massimo Cristofanilli

primary email

mac9795@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Massimo Cristofanilli Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage